Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose paclitaxel

Chemotherapy

Volumn 51, Issue 4, 2005, Pages 200-205

  Juan, Oscar ^a   Rocher, Amparo ^a   Sánchez, Agustín ^a   Sánchez, José Javier ^b   Alberola, Vicente ^a  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b University Hospital of Madrid   (Spain)

Author keywords

Amifostine; Paclitaxel; Pharmacokinetics

Indexed keywords

AMIFOSTINE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; ONDANSETRON; PACLITAXEL; RANITIDINE;

ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CANCER CHEMOTHERAPY; CELL PROTECTION; CIRCULATION TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AMIFOSTINE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; PACLITAXEL; RADIATION-PROTECTIVE AGENTS;

EID: 26044438266     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086597     Document Type: Article

References (23)

1. Sangrajrang S, Fellous A: Taxol resistance. Chemotherapy 2000;46:327-334.
2. Spencer CM, Faulds D: Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48:794-847.
3. Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetics/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-190.
4. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D: A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9:1261-1267.
5. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993;11:2010-2020.
6. Lopes NM, Adams EF, Pitts TW, Bhuyan BK: Cell kill kinetics and cell cycles effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-242.
7. Capizzi RL: Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996;23(suppl 8):2-17.
8. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-2112.
9. DiPaola RS, Schuchter L: Neurologic protection by amifostine. Semin Oncol 1999;26(suppl 7):82-88.
10. Schuchter LM: Current role of protective agents in cancer treatment. Oncology 1997;11:505-512.
11. Selvaggi G, Belani CP: Carboplatin and paclitaxel in non-small cell lung cancer: The role of amifostine. Semin Oncol 1999;26(suppl 7):51-60.
12. Korst AE, van der Sterre ML, Eeltink CM, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ: Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumours. Clin Cancer Res 1997;3:697-703.
13. Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ: Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1998;4:331-336.
14. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J: Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999;17:3038-3047.
15. Andreeva M, Niedmann PD, Binder L, Armstrong VW, Meden H, Binder M, Oellerich M: A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (Taxol) in human serum. Ther Drug Monit 1997;19:327-332.
16. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, O'Connor K, Curtin JP, Crown JP, Hoskins WJ, Spriggs DR: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
17. Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001;7:3942-3947.
18. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Curie V, Maynahan ME, Theodoulou M, Gollug M, Baselga J, Norton L: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-3361.
19. Boddy AV, Melanie JG, Sludden J, Thomas HD, Fishwick K, Wright JG, Plummer ER, Highley M, Calvert AH: Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemother Pharmacol 2001;48:15-21.
20. Mross K, Holländer N, Hauns B, Schumacher M, Maier-Lenz H: The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000;45:463-470.
21. Czejka M, Schueller J, Eder I, Reznicek G, Kraule C, Zeleni U, Freitag R: Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. Anticancer Res 2000;20:3871-3977.
22. Blower PR: 5-HT3-receptor antagonists and the cytochrome P450 system: Clinical implications. Cancer J 2002:8:405-414.
23. Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, Bauknecht T, du Bois A, Meerpohl HG, Hollaender N, Diergarten K: Phase I study of paclitaxel administered as a 1-hour infusion: Toxicity and pharmacokinetics. Semin Oncol 1997;24(suppl 19):S19-16-S19-19.